<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421287</url>
  </required_header>
  <id_info>
    <org_study_id>2020XLA018-2</org_study_id>
    <nct_id>NCT04421287</nct_id>
  </id_info>
  <brief_title>Clinical Study on the Effect of Zhenyuan Capsule on Cardiopulmonary Function in Patients With SCAD</brief_title>
  <official_title>Clinical Study on the Effect of Zhenyuan Capsule on Cardiopulmonary Function in Patients With Stable Coronary Heart Disease With Qi Deficiency and Blood Stasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiyuan Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo trial was adopted, and cardiopulmonary exercise load test&#xD;
      (CPET) was used to detect peak oxygen uptake (PeakVO2) and exercise metabolic equivalent&#xD;
      (METs) to confirm the clinical effect of Zhenyuan capsule on improving cardiopulmonary&#xD;
      endurance in patients with coronary heart disease of qi deficiency and blood stasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double mind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiopulmonary function index change</measure>
    <time_frame>Change from Baseline VO2 peak at 12 weeks / 16 weeks after drug treatment;</time_frame>
    <description>Peak Oxygen Uptake（Peak VO2）；Heart rate、Stroke volume and arteriovenous oxygen difference will be combined to report VO2 peak in mL/kg/min(milliliters of oxygen per kilogram of body weight per minute )；</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stable Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Zhenyuan capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zhenyuan capsule placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zhenyuan capsule</intervention_name>
    <description>0.25g/ tablets, 2 tablets / TID, for 12 weeks</description>
    <arm_group_label>Zhenyuan capsule</arm_group_label>
    <arm_group_label>Zhenyuan capsule placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Results of coronary angiography or spiral CT:Patients with coronary artery stenosis ≥&#xD;
             50%, or with a clear history of myocardial infarction, or stable condition more than&#xD;
             one month after ACS treatment (percutaneous coronary intervention therapy, PCI,&#xD;
             coronary artery bypass graft, CABG)；&#xD;
&#xD;
          -  LVEF≥40%；&#xD;
&#xD;
          -  Angina grade Ⅰ-Ⅱ (CCS grade);&#xD;
&#xD;
          -  The syndrome differentiation of traditional Chinese medicine is the syndrome of qi&#xD;
             deficiency and blood stasis；&#xD;
&#xD;
          -  18 years old ≤ age ≤ 75 years old；&#xD;
&#xD;
          -  In accordance with the risk stratification of cardiac rehabilitation in patients with&#xD;
             coronary heart disease, the patients with moderate and low risk can carry out&#xD;
             cardiopulmonary rehabilitation by exercise；&#xD;
&#xD;
          -  Those who sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute myocardial infarction or unstable angina pectoris, or within one&#xD;
             month after PCI or CABG;&#xD;
&#xD;
          -  Patients with absolute and relative contraindications in accordance with&#xD;
             cardiopulmonary exercise test;&#xD;
&#xD;
          -  Patients who took Zhenyuan capsule in the past 1 month or participated in other&#xD;
             clinical trials in the past 1 month；&#xD;
&#xD;
          -  Renal insufficiency, serum creatinine &gt; 2.5mg / dl in male and &gt; 2.0mg/dl in female；&#xD;
&#xD;
          -  Patients with obvious liver disease or both ALT and AST were 3 times higher than the&#xD;
             normal upper limit；&#xD;
&#xD;
          -  New York heart function (NYHA) grade IV, or patients with recurrent malignant&#xD;
             arrhythmias;&#xD;
&#xD;
          -  Complicated with chronic obstructive pulmonary disease or even respiratory failure, or&#xD;
             complicated with pulmonary infection;&#xD;
&#xD;
          -  Diabetic patients with random blood glucose ≥ 13.7mmol/L or glycosylated hemoglobin ≥&#xD;
             9.5%;&#xD;
&#xD;
          -  Pregnant or preparing pregnant women, lactating women;&#xD;
&#xD;
          -  Patients with acute cerebrovascular diseases; malignant tumors or patients with life&#xD;
             expectancy of less than 1 year; patients with severe hematopoietic diseases; patients&#xD;
             with severe mental illness;&#xD;
&#xD;
          -  For those who are allergic to the known ingredients of the drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Long C Wang, doctorate</last_name>
    <role>Study Chair</role>
    <affiliation>Xiyaun Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NA HUAN, Master</last_name>
    <phone>0086</phone>
    <phone_ext>18353214796</phone_ext>
    <email>HUANNA0323@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiyuan Hospital of China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100091</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>long C Wang, doctorate</last_name>
      <phone>0086-010-6287</phone>
      <phone_ext>9814</phone_ext>
      <email>WCL796@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

